Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Acceleron Pharma Inc's Business Segments
Acceleron Pharma Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 34
Regions Reported
-
Acceleron Pharma Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Royalty93.7%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Royalty | $ 32 | 93.7% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Acceleron Pharma Inc
Acceleron Pharma Inc.
is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines to treat serious and rare diseases.
The company was founded in 2003 and is headquartered in Cambridge, Massachusetts, with other offices located in Toronto, Canada, and Munich, Germany.
The company's main focus is in the field of TGF-β superfamily proteins, which play a vital role in regulating cell growth and differentiation.
Acceleron Pharma is a leader in the research of these proteins, and their work has resulted in the development of a number of investigational drugs that target different disorders.
Currently, Acceleron Pharma's most advanced drug candidate is luspatercept, which is being developed in collaboration with Celgene Corporation.
Luspatercept is a fusion protein that targets the TGF-β protein family and is currently being studied for the treatment of myelodysplastic syndromes (MDS) and beta-thalassemia.
Other key drug candidates being developed by the company include sotatercept, which is being studied for the treatment of pulmonary arterial hypertension, and ACE-083, a muscle-targeting agent being developed for the treatment of several neuromuscular conditions.
Acceleron Pharma has a strong pipeline of drug candidates, with a focus on rare and serious diseases, and has established collaborations with leading pharmaceutical companies such as Celgene, Shire and Biogen.
The company is committed to bringing new therapies to patients with rare diseases, which have very limited treatment options, and has made significant progress in this area.
is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines to treat serious and rare diseases.
The company was founded in 2003 and is headquartered in Cambridge, Massachusetts, with other offices located in Toronto, Canada, and Munich, Germany.
The company's main focus is in the field of TGF-β superfamily proteins, which play a vital role in regulating cell growth and differentiation.
Acceleron Pharma is a leader in the research of these proteins, and their work has resulted in the development of a number of investigational drugs that target different disorders.
Currently, Acceleron Pharma's most advanced drug candidate is luspatercept, which is being developed in collaboration with Celgene Corporation.
Luspatercept is a fusion protein that targets the TGF-β protein family and is currently being studied for the treatment of myelodysplastic syndromes (MDS) and beta-thalassemia.
Other key drug candidates being developed by the company include sotatercept, which is being studied for the treatment of pulmonary arterial hypertension, and ACE-083, a muscle-targeting agent being developed for the treatment of several neuromuscular conditions.
Acceleron Pharma has a strong pipeline of drug candidates, with a focus on rare and serious diseases, and has established collaborations with leading pharmaceutical companies such as Celgene, Shire and Biogen.
The company is committed to bringing new therapies to patients with rare diseases, which have very limited treatment options, and has made significant progress in this area.
Acceleron Pharma Inc. is a prominent biopharmaceutical company that is committed to developing transformative therapies aimed at addressing serious and debilitating diseases. The company operates primarily in two therapeutic areas: hematology and pulmonary diseases. Below is an extensive description of the segments, products, and services provided by Acceleron Pharma.
Segments and Therapeutic Areas
1. Hematology
The hematology segment of Acceleron Pharma is dedicated to developing therapies to treat various blood disorders. Key focus areas include:
- Beta-Thalassemia: A genetic blood disorder that leads to reduced hemoglobin levels and can result in severe anemia.
- Sickle Cell Disease: A hereditary blood disorder characterized by the abnormal shape of red blood cells, which can cause pain and other severe complications.
Pulmonary Diseases
The pulmonary segment concentrates on therapies for disorders that affect the respiratory system. Specific conditions targeted include:
- Pulmonary Arterial Hypertension (PAH): A progressive disease characterized by high blood pressure in the pulmonary arteries, leading to fatigue, shortness of breath, and heart failure.
- Chronic Obstructive Pulmonary Disease (COPD): A group of lung diseases, including emphysema and chronic bronchitis, which obstruct airflow and cause breathing difficulties.
Products and Services
Product Portfolio
1. REBLOZYLe (luspatercept-aamt)
- Indication: Approved for use in adult patients with beta-thalassemia who require regular red blood cell transfusions.
- Mechanism: REBLOZYLe acts as a first-in-class erythroid maturation agent, promoting the production of red blood cells and reducing the need for transfusions.
2. Sotatercept
- Indication: Developed for potential use in treating pulmonary arterial hypertension (PAH) and other forms of pulmonary hypertension (PH).
- Mechanism: Sotatercept functions as a TGF-beta superfamily ligand trap, with promising results observed in Phase 2 clinical trials, indicating its potential to improve pulmonary vascular resistance and exercise capacity in patients.
3. ACE-083
- Indication: Investigational therapy aimed at treating Charcot-Marie-Tooth (CMT) disease.
- Mechanism: ACE-083 is designed as a selective muscle agent that enhances muscle strength and function in patients suffering from this genetic disorder, which leads to progressive muscle weakness.
4. ACE-2494
- Indication: Developed for targeting neuromuscular disorders, including facioscapulohumeral muscular dystrophy (FSHD).
- Mechanism: This compound serves as an ActRIIA antagonist, potentially addressing the underlying muscle atrophy and weakness associated with these disorders.
Clinical Development and Commercialization Services
In addition to its therapeutics, Acceleron Pharma provides a suite of services to facilitate drug development and commercialization for its partners:
- Clinical Trial Design and Execution: Expertise in crafting robust clinical protocols and overseeing trial operations to ensure compliance and scientific integrity.
- Regulatory Affairs: Navigating the complex regulatory landscape to secure approvals from government and health authorities for drug candidates.
- Project Management: Comprehensive management of timelines, budgets, and resources to propel projects from conception through to commercialization.
- Commercial Strategic Planning: Strategic advice on market positioning, product differentiation, and pricing strategies for new therapies.
- Market Access Consulting: Providing guidance on reimbursement strategies and navigating the payer landscape to ensure patient access to therapies.
Conclusion
Acceleron Pharma Inc. stands out in the biopharmaceutical landscape, with its focused approach on developing innovative therapies for critical health conditions in hematology and pulmonary diseases. The company’s robust product portfolio, combined with comprehensive development and commercialization services, underscores its commitment to improving patient outcomes and addressing unmet medical needs. Through its pioneering work and dedication to transformative therapies, Acceleron Pharma plays a vital role in enhancing the lives of patients impacted by serious diseases.
Segments and Therapeutic Areas
1. Hematology
The hematology segment of Acceleron Pharma is dedicated to developing therapies to treat various blood disorders. Key focus areas include:
- Beta-Thalassemia: A genetic blood disorder that leads to reduced hemoglobin levels and can result in severe anemia.
- Sickle Cell Disease: A hereditary blood disorder characterized by the abnormal shape of red blood cells, which can cause pain and other severe complications.
Pulmonary Diseases
The pulmonary segment concentrates on therapies for disorders that affect the respiratory system. Specific conditions targeted include:
- Pulmonary Arterial Hypertension (PAH): A progressive disease characterized by high blood pressure in the pulmonary arteries, leading to fatigue, shortness of breath, and heart failure.
- Chronic Obstructive Pulmonary Disease (COPD): A group of lung diseases, including emphysema and chronic bronchitis, which obstruct airflow and cause breathing difficulties.
Products and Services
Product Portfolio
1. REBLOZYLe (luspatercept-aamt)
- Indication: Approved for use in adult patients with beta-thalassemia who require regular red blood cell transfusions.
- Mechanism: REBLOZYLe acts as a first-in-class erythroid maturation agent, promoting the production of red blood cells and reducing the need for transfusions.
2. Sotatercept
- Indication: Developed for potential use in treating pulmonary arterial hypertension (PAH) and other forms of pulmonary hypertension (PH).
- Mechanism: Sotatercept functions as a TGF-beta superfamily ligand trap, with promising results observed in Phase 2 clinical trials, indicating its potential to improve pulmonary vascular resistance and exercise capacity in patients.
3. ACE-083
- Indication: Investigational therapy aimed at treating Charcot-Marie-Tooth (CMT) disease.
- Mechanism: ACE-083 is designed as a selective muscle agent that enhances muscle strength and function in patients suffering from this genetic disorder, which leads to progressive muscle weakness.
4. ACE-2494
- Indication: Developed for targeting neuromuscular disorders, including facioscapulohumeral muscular dystrophy (FSHD).
- Mechanism: This compound serves as an ActRIIA antagonist, potentially addressing the underlying muscle atrophy and weakness associated with these disorders.
Clinical Development and Commercialization Services
In addition to its therapeutics, Acceleron Pharma provides a suite of services to facilitate drug development and commercialization for its partners:
- Clinical Trial Design and Execution: Expertise in crafting robust clinical protocols and overseeing trial operations to ensure compliance and scientific integrity.
- Regulatory Affairs: Navigating the complex regulatory landscape to secure approvals from government and health authorities for drug candidates.
- Project Management: Comprehensive management of timelines, budgets, and resources to propel projects from conception through to commercialization.
- Commercial Strategic Planning: Strategic advice on market positioning, product differentiation, and pricing strategies for new therapies.
- Market Access Consulting: Providing guidance on reimbursement strategies and navigating the payer landscape to ensure patient access to therapies.
Conclusion
Acceleron Pharma Inc. stands out in the biopharmaceutical landscape, with its focused approach on developing innovative therapies for critical health conditions in hematology and pulmonary diseases. The company’s robust product portfolio, combined with comprehensive development and commercialization services, underscores its commitment to improving patient outcomes and addressing unmet medical needs. Through its pioneering work and dedication to transformative therapies, Acceleron Pharma plays a vital role in enhancing the lives of patients impacted by serious diseases.